title: Efficacy of 5α-reductase inhibitors for patients with large benign prostatic hyperplasia (>80 mL) after transurethral resection of the prostate.
abstract: OBJECTIVE
  To prospectively evaluate 5α-reductase inhibitors (5αRIs) for benign prostatic hyperplasia (BPH) patients with a large prostate (>80 mL) after transurethral resection of the prostate (TURP).
  
  
  METHODS
  Eighty-seven patients were recruited from January 2007 to October 2014. Patients were randomized into a trial and a control group. The trial group was treated with 5αRIs for 3 years after TURP, while the control group received a placebo. We evaluated the indicators before, peri and after TURP.
  
  
  RESULTS
  There were no significant differences in the indicators before and peri-TURP. Six months later, there were significant differences in PSA and hematuria (HU). Three years after TURP, there were significant differences in prostate volume (PV), level of prostate-specific antigen (PSA), the maximum flow rate (Qm), and HU between the trial and control groups. Additionally, there were significant differences in the PV, PSA, international prostate symptom score (IPSS), patient quality of life (QoL) in the trial group alone between those treated with finasteride and those treated with dutasteride.
  
  
  CONCLUSIONS
  After TURP for large BPH, administration of 5αRIs for 3 years improved PV, PSA, Qm and HU. Additionally, dutasteride produced superior improvements in PV, PSA, IPSS and QoL compared with finasteride.
authors.affiliation: a Department of Urology , Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine , Shanghai , P.R. China .
authors.forename: Xiaoqiang
authors.initials: X
authors.lastname: Qian
authors.affiliation: a Department of Urology , Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine , Shanghai , P.R. China .
authors.forename: Guopeng
authors.initials: G
authors.lastname: Yu
authors.affiliation: b Department of Urology , Kongjiang Hospital , Shanghai , P.R. China .
authors.forename: Yu
authors.initials: Y
authors.lastname: Qian
authors.affiliation: a Department of Urology , Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine , Shanghai , P.R. China .
authors.forename: Ding
authors.initials: D
authors.lastname: Xu
authors.affiliation: a Department of Urology , Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine , Shanghai , P.R. China .
authors.forename: Hailong
authors.initials: H
authors.lastname: Liu
authors.affiliation: a Department of Urology , Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine , Shanghai , P.R. China .
authors.forename: Xiangjie
authors.initials: X
authors.lastname: Kong
authors.affiliation: c Department of Ultrasound in Medicine , Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine , Shanghai , P.R. China .
authors.forename: Yunkai
authors.initials: Y
authors.lastname: Zhu
authors.affiliation: d Department of Urology , Ninth Hospital Affiliated to Shanghai Jiaotong University School of Medicine , Shanghai , P.R. China , and.
authors.forename: Zhong
authors.initials: Z
authors.lastname: Wang
authors.affiliation: e Department of Urology , Tenth Hospital Affiliated to Shanghai Tongji University School of Medicine , Shanghai , P.R. China.
authors.forename: Junhua
authors.initials: J
authors.lastname: Zheng
authors.affiliation: a Department of Urology , Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine , Shanghai , P.R. China .
authors.forename: Jun
authors.initials: J
authors.lastname: Qi
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D011446:Prospective Studies; D011467:Prostate / Q000033:anatomy & histology; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000601:surgery; D020728:Transurethral Resection of Prostate
chemical_list: D058891:5-alpha Reductase Inhibitors
keywords: 5α-reductase inhibitors; prostatic hyperplasia; transurethral resection of prostate